Research chemicalStimulantResearch chemicalAmphetamine

Methamnetamine (MNA)

Also known as MNA · Methamnetamine · Methylnaphetamine · PAL-1046

Written by enwyReviewed 4 Aug 20261 sources0 comments

Methamnetamine (MNA, methylnaphetamine) is the N-methylated analogue of naphthylaminopropane, a stimulant-entactogen with a large naphthalene ring in place of the amphetamine benzene ring. It is a potent triple monoamine releaser sold as a research chemical, with negligible human data.

01 Overview

Methamnetamine replaces the phenyl ring of methamphetamine with a naphthyl group, a modification that produces a potent releaser of serotonin, noradrenaline and dopamine. In vitro it behaves like a strong, non-selective monoamine releaser, giving a combined stimulant and entactogenic profile.

It appeared as a designer stimulant with no clinical study behind it. The strong serotonergic releasing activity raises particular concern about serotonin toxicity and neurotoxicity by analogy to related releasers, but direct human evidence is absent and the entries below rest on in vitro data and anecdote.

02 Mechanism

Potent non-selective releaser of serotonin, noradrenaline and dopamine; the naphthyl ring enhances releasing potency across all three transporters.

03 Dosing

Tier	Dose	Route	Notes
Light	15–40 mg	Insufflated	Unstudied; not recommended given serotonergic potency.
Common	20–60 mg	Oral	Anecdotal only; no validated dosing.

04 Effects

Effect	Magnitude	Evidence
StimulationStrong energetic stimulation.		Anecdotal
Entactogenic mood liftReported euphoria and emotional warmth.		Anecdotal
Increased sociabilityTalkativeness and sociability.		Anecdotal

05 Side effects

Effect	Severity	Frequency	Evidence
Serotonin toxicity riskPotent serotonin release raises serotonin-syndrome risk, especially in combination.	Life-threatening	Unknown; risk with serotonergic combinations	Unconfirmed
Cardiovascular strainTachycardia and hypertension.	Severe	Common	Anecdotal
Neurotoxicity concernPotent serotonin releasers of this type raise concern for serotonergic neurotoxicity.	Severe	Unknown	Unconfirmed

06 Legal status

United States

Not federally scheduled

Possible Federal Analogue Act exposure. · as of Jan 2026

United Kingdom

Class B

Generic amphetamine provisions likely apply. · as of Jan 2026

07 References

Naphthyl-substituted amphetamines as monoamine releasersPubMed search

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.